<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18360">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961310</url>
  </required_header>
  <id_info>
    <org_study_id>AOIt/2012/JPL-01</org_study_id>
    <secondary_id>2013-A00888-37</secondary_id>
    <nct_id>NCT01961310</nct_id>
  </id_info>
  <brief_title>Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With DR4 Homozygous Rheumatoid Arthritis</brief_title>
  <acronym>MICROPOLY</acronym>
  <official_title>Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With DR4 Homozygous Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare the intestinal microbiota in newly diagnosed
      patients with homozygous DR4 rheumatoid arthritis (RA)with that from DR4 homozygous
      individuals without RA.

      The first analysis will compare the proportion of filamentous bacteria in the intestinal
      microbiota between the two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are :

        -  A. To compare between the two groups :

        -  a. The proportion of Proteus mirabilis in the intestinal microbiota

        -  b . The proportion of species producing peptidyl arginine deaminase (PAD ) in the
           intestinal microbiota

        -  c . The number of species found in the intestinal microbiota

        -  B. To evaluate bacterial translocation (from the digestive tract) in patients with
           newly diagnosed, homozygous DR4 RA and homozygous DR4 healthy volunteers without RA.
           (Bacterial translocation is a phenomenon in which live bacteria or a part of bacteria
           (e.g. LPS teichoïc acid) cross the intestinal barrier and reach the bloodstream.)

        -  C. To describe the ecology of the intestinal microbiota of patients with homozygous DR4
           RA (characterization of species found according to their respiratory metabolism,
           according to their bacteriological characteristics, and according to wether or not the
           species are found significantly more frequently in patients with RA than in individuals
           without RA).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>The proportion of filamentous bacteria in the intestinal microbiota</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of Proteus mirabilis in the intestinal microbiota</measure>
    <time_frame>baseline (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of species producing peptidyl arginine desaminase (PAD) in the intestinal microbiota</measure>
    <time_frame>baseline (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of species found in the intestinal microbiota</measure>
    <time_frame>baseline (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of bacterial translocation</measure>
    <time_frame>baseline (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the ecology of intestinal microbiota</measure>
    <time_frame>baseline (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diversity indices according to species and/or functional groups.  The general goal is to provide a description of the functional differences between groups.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>DR4 homozygous RA</arm_group_label>
    <description>This group is composed of 25 patients with RA and who are homozygous for the HLA-DR4 allele.  The diagnosis of RA is based upon the American College of Rheumatology criteria.
Intervention: Plasma analysis for bacterial translocation
Intervention: Stool analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR4 homozygous volunteer</arm_group_label>
    <description>This group is composed of 25 healthy volunteers who are homozygous for the HLA-DR4 allele and who do not have RA.
Intervention: Plasma analysis for bacterial translocation
Intervention: Stool analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma analysis for bacterial translocation</intervention_name>
    <description>1 ml of plasma will be obtained (blood sample).  DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.</description>
    <arm_group_label>DR4 homozygous RA</arm_group_label>
    <arm_group_label>DR4 homozygous volunteer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stool analysis</intervention_name>
    <description>DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.</description>
    <arm_group_label>DR4 homozygous RA</arm_group_label>
    <arm_group_label>DR4 homozygous volunteer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 50 adult subjects will be included: 25 with newly diagnosed RA (&lt;12 months)
        based on the American College of Rheumatology criteria, and 25 healthy volunteers without
        RA.

        All subjects are homozygous for the HLA-DR4 allele.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for RA patients:

          -  The patient was correctly informed

          -  The patient must have given his/her informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  Homozygous for the HLA-DR4 allele

          -  No antibiotic treatments within the 30 days preceding inclusion

          -  RA diagnosis made within the past 12 months

        Exclusion Criteria for RA patients:

          -  The patient has participated in another study within the past 3 months

          -  The patient is under judicial protection, or any kind of guardianship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  The patient is pregnant, parturient, or breastfeeding

          -  The patient is not homozygous for the HLA-DR4 allele

          -  The patient has taken antibiotics in the 30 days preceding inclusion

          -  RA was diagnosed more than 12 months ago

        Inclusion Criteria for healthy volunteers (HV):

          -  The HV was correctly informed

          -  The HV must have given his/her informed and signed consent

          -  The HV must be insured or beneficiary of a health insurance plan

          -  Homozygous for the HLA-DR4 allele

          -  No antibiotic treatments within the 30 days preceding inclusion

          -  Does not have RA

        Exclusion Criteria for HVs:

          -  The HV has participated in another study within the past 3 months

          -  The HV is under judicial protection, or any kind of guardianship

          -  The HV refuses to sign the consent

          -  It is impossible to correctly inform the HV

          -  The HV is pregnant, parturient, or breastfeeding

          -  The HV is not homozygous for the HLA-DR4 allele

          -  The HV has taken antibiotics in the 30 days preceding inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Dunyach-Rempy, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Philippe Lavigne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Dunyach-Remy, PharmD, PhD</last_name>
    <phone>+33.(0)4.66.02.81.49</phone>
    <email>dunyachcatherine@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christian Jorgensen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Marie Pers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Le Blay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosanna Ferreira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unité U1047 &quot;Bacterial virulence and infectious diseases&quot;, UFR de Médecine</name>
      <address>
        <city>Nîmes Cedex 2</city>
        <zip>30908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial translocation</keyword>
  <keyword>intestinal microbiota</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
